Английская Википедия:Belinostat

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Infobox drug

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.[1]

It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.[2]

In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[3] Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.[4] Belinostat has been granted orphan drug and fast track designation by the FDA,[5] and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014.[2] It is not approved in Europe Шаблон:As of.[6]

The approved pharmaceutical formulation is given intravenously.[7]Шаблон:Rp Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele.[7]Шаблон:Rp

References

Шаблон:Reflist

Шаблон:Intracellular chemotherapeutic agents Шаблон:HDAC inhibitors

Шаблон:Antineoplastic-drug-stub